Janssen Vaccines & Prevention B.V.

CAGE Code: H1N64

NCAGE Code: H1N64

Status: Active

Type: Manufacturer

Summary

Janssen Vaccines & Prevention B.V. is an Active Manufacturer with the Cage Code H1N64.

Address

Archimedesweg 4
2048
Leiden
2333 CN
Netherlands

Points of Contact

No Points of Contact...

Related Information

No Related Information...

Associated CAGE Codes People who viewed this 'CAGE Code' also viewed...

CAGE Code FAQ Frequently Asked Questions (FAQ) for CAGE H1N64

What is CAGE Code H1N64?
H1N64 is the unique identifier used by NATO Organizations to reference the physical entity known as Janssen Vaccines & Prevention B.V. located at Archimedesweg 4, 2048, Leiden, 2333 CN, Netherlands.
Who is CAGE Code H1N64?
H1N64 refers to Janssen Vaccines & Prevention B.V. located at Archimedesweg 4, 2048, Leiden, 2333 CN, Netherlands.
Where is CAGE Code H1N64 Located?
CAGE Code H1N64 is located in Leiden, Netherlands.

Contracting History for CAGE H1N64 Contracting History for CAGE H1N64 Most Recent 25 Records

HHSN272200800056C
Advanced Development Of Multivalent Filovirus (Ebola And Marburg) Hemorrhagic Fever Vaccines
12 Sep 2018
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$76,122,958.12
HHSN272200800056C
Advanced Development Of Multivalent Filovirus (Ebola And Marburg) Hemorrhagic Fever Vaccines
8 Aug 2023
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$69,856,435.90
HHSO100201500008C
Nce To Extend Pop To 9/14/2020
25 Nov 2019
Office Of Acq Mgmt Policy
Department Of Health And Human Services (Hhs)
$49,551,141.00
HHSO100201700013C
Remove Hhsar Clause 352.232-71 - Electronic Submission Of Payment Requests
23 Jun 2022
Barda - Aspr / Daappo / Barda Dcma
Department Of Health And Human Services (Hhs)
$132,282,550.00
HHSN272200800056C
Advanced Development Of Multivalent Filovirus (Ebola And Marburg) Hemorrhagic Fever Vaccines
19 Sep 2018
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$75,773,118.58
HHSN272200800056C
Advanced Development Of Multivalent Filovirus (Ebola And Marburg) Hemorrhagic Fever Vaccines
13 Sep 2023
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$69,856,435.90
HHSN272200800056C
Advanced Development Of Multivalent Filovirus (Ebola And Marburg) Hemorrhagic Fever Vaccines
5 Sep 2019
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$74,402,221.58
HHSN272200800056C
Advanced Development Of Multivalent Filovirus (Ebola And Marburg) Hemorrhagic Fever Vaccines
22 Jul 2019
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$74,767,730.77
HHSO100201500008C
Mod Will Provide A No Cost Extension (Nce) For 8 Months For Clin0001 Due To The Delay Of Material Availability For Repeating The Formulation Robustness Study Under Task 1.1.3.1, Which Will Impact The Overall Timelines Of The Study For Clin0001. T
11 Mar 2021
Barda - Aspr / Daappo / Barda Dcma
Department Of Health And Human Services (Hhs)
$49,551,141.00
HHSO100201700013C
Igf::Ot::Igf
25 Jul 2018
Office Of Acq Mgmt Policy
Department Of Health And Human Services (Hhs)
$123,107,803.00
HHSO100201700013C
The Purpose Of Modification 2 Is To Additional Funds To Clin 0004. These Funds Will Be Used For The Preparation Of Datasets, Analyses And Clinical Study Reports From Studies Ebl2004 (Prevac) And Ebl2009 (Uganda) Per Request Of Fda.
6 Apr 2020
Office Of Acq&Mgmt Policy
Department Of Health And Human Services (Hhs)
$125,333,969.00
HHSO100201500008C
Nce To Extend Pop To 3/14/2021
14 Sep 2020
Office Of Acq&Mgmt Policy
Department Of Health And Human Services (Hhs)
$49,551,141.00
HHSN272200800056C
Advanced Development Of Multivalent Filovirus (Ebola And Marburg) Hemorrhagic Fever Vaccines
25 Aug 2022
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$70,299,100.90
HHSO100201700013C
The Purpose Of This Modification Is To Extend The Period Of Performance For The Base Period, Option Period 2 And Option Period 3.
14 Sep 2023
Barda - Aspr / Daappo / Barda Dcma
Department Of Health And Human Services (Hhs)
$132,282,550.00
HHSN272200800056C
Advanced Development Of Multivalent Filovirus (Ebola And Marburg) Hemorrhagic Fever Vaccines
16 Sep 2021
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$69,687,474.29
HHSO100201700013C
Incorporate Technical Changes To Sow; Clin0001, Clin0004 And Clin0005 And Add Hhsar Clause 352.232-71 - Electronic Submission Of Payment Requests
8 Apr 2022
Barda - Aspr / Daappo / Barda Dcma
Department Of Health And Human Services (Hhs)
$132,282,550.00
HHSO100201700013C
Janssen Will Conduct Development Activities Necessary To Achieve Licensure Of The Vaccine And Manufacture And Fill/Finish Vaccine To Be Stored As Vendor Managed Inventory (Vmi) Or Delivered To The Strategic National Stockpile (Sns). The Contract Opti
5 Mar 2021
Office Of Acq Mgmt Policy
Department Of Health And Human Services (Hhs)
$132,282,550.00
HHSO100201500008C
Upstream And Downstream Process Development Activities For Ad26.Zebov
24 Jul 2019
Office Of Acq Mgmt Policy
Department Of Health And Human Services (Hhs)
$49,551,141.00